Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained its Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of the expected 7-year findings from Edwards’ PARTNER 3 study, which is set to be presented on October 27 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
With follow-up spanning ten years, Edwards’ historic PARTNER 3 trial compares surgical aortic valve replacement (SAVR) with its Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients.
According to Piper Sandler, upcoming data will likely show that TAVR is not inferior to SAVR on these endpoints, which could render the findings a “non-event with minimal commercial implications.”
Edwards Lifesciences Corporation develops and sells patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for the treatment of structural heart disease and critical care.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
